Under the National Policy for Rare Diseases (NPRD), the Government of India provides one-time financial assistance of up to ₹50 lakh per patient across designated Centers of Excellence (CoEs). However, for progressive conditions requiring continuous therapy, this funding ceiling is quickly exhausted with official records indicating that dozens of patients have already depleted their allocated financial assistance.
The transition toward indigenous manufacturing is delivering dramatic pricing relief and demonstrating the clinical viability of localized production. Gaucher Disease: Local formulation synthesis has compressed annual treatment expenditures from ₹1.8–₹3.6 crore down to ₹3–₹6 lakh per patient.
Spinal Muscular Atrophy (SMA): In Kerala’s public procurement, the cost for oral risdiplam dropped from ₹5.52 lakh per bottle for the innovator product down to ₹8,000 per bottle for the Indian generic alternative developed by NatcoPharma.
Healthcare economists, clinical geneticists, and patient advocacy groups, including the Indian Organisation for Rare Diseases (IORD), highlight that the traditional model relying on individual patient subsidies for high-cost imports is fiscally unsustainable. The emerging consensus urges an integrated policy shift: leveraging advance purchase commitments, fast-tracked regulatory pathways, and targeted production-linked incentives to de-risk domestic development. By guaranteeing institutional demand and fostering indigenous formulation capacities, India can bridge the critical gap between API manufacturing leadership and affordable clinical access for rare disease communities nationwide.
A major paradigm shift is emerging across India’s rare disease landscape as domestic pharmaceutical manufacturing significantly undercuts the exorbitant costs of imported orphan drugs. While Indian manufacturers synthesize key active pharmaceutical ingredients (APIs) for more than 400 U.S. FDA-approved orphan drugs, domestic patients have historically faced catastrophic financial barriers, relying on multinational imports that often cost crores of rupees annually for lifelong management.
Under the National Policy for Rare Diseases (NPRD), the Government of India provides one-time financial assistance of up to ₹50 lakh per patient across designated Centers of Excellence (CoEs). However, for progressive conditions requiring continuous therapy, this funding ceiling is quickly exhausted with official records indicating that dozens of patients have already depleted their allocated financial assistance.
The transition toward indigenous manufacturing is delivering dramatic pricing relief and demonstrating the clinical viability of localized production. Gaucher Disease: Local formulation synthesis has compressed annual treatment expenditures from ₹1.8–₹3.6 crore down to ₹3–₹6 lakh per patient.
Spinal Muscular Atrophy (SMA): In Kerala’s public procurement, the cost for oral risdiplam dropped from ₹5.52 lakh per bottle for the innovator product down to ₹8,000 per bottle for the Indian generic alternative developed by NatcoPharma.
Healthcare economists, clinical geneticists, and patient advocacy groups, including the Indian Organisation for Rare Diseases (IORD), highlight that the traditional model relying on individual patient subsidies for high-cost imports is fiscally unsustainable. The emerging consensus urges an integrated policy shift: leveraging advance purchase commitments, fast-tracked regulatory pathways, and targeted production-linked incentives to de-risk domestic development. By guaranteeing institutional demand and fostering indigenous formulation capacities, India can bridge the critical gap between API manufacturing leadership and affordable clinical access for rare disease communities nationwide.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
